EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC-ND 4.0

Development, Validation, and Clinical Application of an HPLC-Based Method for Determining Adenosine Deaminase Activity in Adenosine Deaminase Deficiency-Severe Combined Immunodeficiency

Maria Petrik iD, Evgeny Litvin, Andrey Osipyants, Aleksandra Filkova, Yulia Rodina, Dmitrii Blinov, Nikolay Grachev, Anna Shcherbina

The Journal of Applied Laboratory Medicine · 01.07.2026 · 11 (4) · 758-769

DOI: 10.1093/jalm/jfag037 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift The Journal of Applied Laboratory Medicine, online erschienen am 21.04.2026. Verfasst von Maria Petrik und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia. Hauptthemen laut MEDLINE: Adenosine Deaminase, Severe Combined Immunodeficiency, Agammaglobulinemia, Dried Blood Spot Testing. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adenosine deaminase (ADA) deficiency is a rare genetic condition leading to severe combined immunodeficiency. Timely and accurate quantification of ADA activity is crucial for both diagnosis and treatment monitoring. This study describes the development and analytical validation of a high-performance liquid chromatography (HPLC)-based method for measuring ADA activity in dried blood spot (DBS) samples.

Methods

ADA activity was quantified by measuring the enzymatic conversion of adenosine to inosine and hypoxanthine, followed by chromatographic separation and detection. Method validation was conducted according to current bioanalytical guidelines and included assessment of selectivity, linearity, sensitivity, precision, trueness, extraction recovery, and stability. The study involved 3 groups of samples taken from healthy pediatric donors (n = 116), carriers of pathogenic mutations (n = 13), and patients with genetically confirmed ADA deficiency (n = 11).

Results

The assay demonstrated high selectivity and linearity over the tested concentration ranges (coefficient of determination > 0.99 for both analytes). The lower limit of quantification was 0.312 μg/mL (2.29 μmol/L) for hypoxanthine and 0.5 μg/mL (1.86 μmol/L) for inosine. A reference interval for ADA activity in DBS was established at 14.94 to 43.28 nmol/h/mg. The mean ADA activity was 25.06 nmol/h/mg of protein in the control group, 14.08 nmol/h/mg in mutation carriers, and 2.18 nmol/h/mg in patients with ADA deficiency.

Conclusions

The developed method allows precise and reliable determination of ADA activity in DBS. It can be applied for the diagnosis and monitoring of patients with ADA deficiency, as well as in scientific studies related to purine metabolism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine DeaminaseSevere Combined ImmunodeficiencyAgammaglobulinemiaDried Blood Spot TestingHumansChromatography, High Pressure LiquidReproducibility of ResultsInosineFemaleMaleChildChild, PreschoolInfantSensitivity and SpecificityHypoxanthineAdenosineMutationLimit of Detection

Substanzen

Adenosine DeaminaseInosineHypoxanthineAdenosine

Autor:innen und Institutionen

  • Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
  • Sechenov University, Moscow, Russia.

ORCID-Profile: Maria Petrik

Förderung

  • Russian Science Foundation

Zitieren

APA

Petrik, M., Litvin, E., Osipyants, A., Filkova, A., Rodina, Y., Blinov, D., Grachev, N., & Shcherbina, A. (2026). Development, Validation, and Clinical Application of an HPLC-Based Method for Determining Adenosine Deaminase Activity in Adenosine Deaminase Deficiency-Severe Combined Immunodeficiency. The Journal of Applied Laboratory Medicine, 11(4), 758-769. https://doi.org/10.1093/jalm/jfag037

Vancouver

Petrik M, Litvin E, Osipyants A, Filkova A, Rodina Y, Blinov D, et al. Development, Validation, and Clinical Application of an HPLC-Based Method for Determining Adenosine Deaminase Activity in Adenosine Deaminase Deficiency-Severe Combined Immunodeficiency. The Journal of Applied Laboratory Medicine. 2026;11(4):758-769. doi:10.1093/jalm/jfag037

BibTeX
@article{Petrik2026,
  author = {Petrik, Maria and Litvin, Evgeny and Osipyants, Andrey and Filkova, Aleksandra and Rodina, Yulia and Blinov, Dmitrii and Grachev, Nikolay and Shcherbina, Anna},
  title = {Development, Validation, and Clinical Application of an HPLC-Based Method for Determining Adenosine Deaminase Activity in Adenosine Deaminase Deficiency-Severe Combined Immunodeficiency},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2026},
  volume = {11},
  number = {4},
  pages = {758--769},
  doi = {10.1093/jalm/jfag037}
}
Kostenlos starten →